These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

454 related articles for article (PubMed ID: 19167852)

  • 1. [Yellow fever vaccination: update on rare and severe adverse effects].
    Receveur MC; Bruyand M; Pistone T; Malvy D
    Med Mal Infect; 2009 Apr; 39(4):234-41. PubMed ID: 19167852
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adverse event reports following yellow fever vaccination.
    Lindsey NP; Schroeder BA; Miller ER; Braun MM; Hinckley AF; Marano N; Slade BA; Barnett ED; Brunette GW; Horan K; Staples JE; Kozarsky PE; Hayes EB
    Vaccine; 2008 Nov; 26(48):6077-82. PubMed ID: 18809449
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention of yellow fever in persons traveling to the tropics.
    Monath TP; Cetron MS
    Clin Infect Dis; 2002 May; 34(10):1369-78. PubMed ID: 11981733
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Review of the risks and benefits of yellow fever vaccination including some new analyses.
    Monath TP
    Expert Rev Vaccines; 2012 Apr; 11(4):427-48. PubMed ID: 22551029
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Yellow fever: epidemiology and prevention.
    Barnett ED
    Clin Infect Dis; 2007 Mar; 44(6):850-6. PubMed ID: 17304460
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Yellow fever vaccine-associated viscerotropic disease and death in Spain.
    Doblas A; Domingo C; Bae HG; Bohórquez CL; de Ory F; Niedrig M; Mora D; Carrasco FJ; Tenorio A
    J Clin Virol; 2006 Jun; 36(2):156-8. PubMed ID: 16597510
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Yellow fever vaccination: some thoughts on how much is enough [Vaccine 23 (2005) 3908-3914].
    Martins RM; Galler R; Freire MS; Camacho LA; de Lourdes S Maia M; Homma A
    Vaccine; 2007 Jan; 25(1):10-1. PubMed ID: 16448728
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Yellow fever vaccination: how much is enough?
    Massad E; Coutinho FA; Burattini MN; Lopez LF; Struchiner CJ
    Vaccine; 2005 Jun; 23(30):3908-14. PubMed ID: 15917112
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Yellow fever vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Staples JE; Gershman M; Fischer M;
    MMWR Recomm Rep; 2010 Jul; 59(RR-7):1-27. PubMed ID: 20671663
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Yellow fever as an endemic/epidemic disease and priorities for vaccination.
    Monath TP
    Bull Soc Pathol Exot; 2006 Dec; 99(5):341-7. PubMed ID: 17253051
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Efficacy and safety of vaccination against yellow fever of persons traveling to endemic areas].
    Dabrowska MM; Flisiak R
    Przegl Epidemiol; 2010; 64(2):319-22. PubMed ID: 20731245
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Surveillance system for adverse events following immunization against yellow fever in Burkina Faso in 2008. Good practice recommendations].
    Yaméogo TM; Breugelmans JG; Kambou JL; Badolo O; Tiendrebéogo S; Traoré E; Avokey F; Yactayo S
    Med Trop (Mars); 2009 Aug; 69(4):320-1. PubMed ID: 19725376
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Yellow fever vaccination coverage among children in Brazilian capitals.
    Veras MA; Flannery B; de Moraes JC; da Silva Teixeira AM; Luna EJ;
    Vaccine; 2010 Sep; 28(39):6478-82. PubMed ID: 20674878
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Yellow fever vaccines and international travelers.
    Barnett ED; Wilder-Smith A; Wilson ME
    Expert Rev Vaccines; 2008 Jul; 7(5):579-87. PubMed ID: 18564013
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Viscerotropic disease following yellow fever vaccination in Peru.
    Whittembury A; Ramirez G; Hernández H; Ropero AM; Waterman S; Ticona M; Brinton M; Uchuya J; Gershman M; Toledo W; Staples E; Campos C; Martínez M; Chang GJ; Cabezas C; Lanciotti R; Zaki S; Montgomery JM; Monath T; Hayes E
    Vaccine; 2009 Oct; 27(43):5974-81. PubMed ID: 19679215
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Viscerotropic and neurotropic disease following vaccination with the 17D yellow fever vaccine, ARILVAX.
    Kitchener S
    Vaccine; 2004 Jun; 22(17-18):2103-5. PubMed ID: 15149765
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Yellow fever].
    Wiercińska-Drapało A
    Przegl Epidemiol; 2004; 58 Suppl 1():101-5. PubMed ID: 15807166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute viscerotropic disease following vaccination against yellow fever.
    Hayes EB
    Trans R Soc Trop Med Hyg; 2007 Oct; 101(10):967-71. PubMed ID: 17669451
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Yellow fever vaccine - how does it work and why do rare cases of serious adverse events take place?
    Barrett AD; Teuwen DE
    Curr Opin Immunol; 2009 Jun; 21(3):308-13. PubMed ID: 19520559
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Late vaccination against yellow fever of travelers visiting endemic countries.
    Krief I; Goldblatt JG; Paz A; Potasman I
    Travel Med Infect Dis; 2006 Mar; 4(2):94-8. PubMed ID: 16887731
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.